Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jul 17, 2013, no change to tracked fieldsv11-v12
  2. Primary completion date changed from estimate of Jul 2009 to Jun 2010
    • Study completion date changed from estimate of Apr 2010 to Feb 2011
    • Trial status: Active, Not Recruiting to Completed
    v10
  3. Enrollment target: estimated 220 to confirmed 225
    • Primary completion date: Jul 2010 to Jul 2009
    • Study completion date: Dec 2010 to Apr 2010
    • Secondary endpoints: 15 to 16
    v9
  4. Study title expanded, about 1 wordv8
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jul 2010
    • Study completion date: Dec 2010
    • Study arms: 0 to 2
    • Eligibility criteria expanded, about 2 words
    v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
  3. 2 versions Re-verified since Jan 29, 2007, no change to tracked fieldsv3-v4
  4. Study title revisedv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate whether a monotherapy of boosted darunavir is able to maintain the virological success until 48 weeks in comparison to a standard therapy 2 INTI + darunavir/r in HIV infected patients with full viral suppression.
Trial Details
NCT Number NCT00421551
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Tibotec Pharmaceutical Limited
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 225 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov